EMA/142976/2024

European Medicines Agency decision

P/0123/2024

of 11 April 2024

on the acceptance of a modification of an agreed paediatric investigation plan for aficamten (EMEA-002958-PIP01-21-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0123/2024

of 11 April 2024

on the acceptance of a modification of an agreed paediatric investigation plan for aficamten (EMEA-002958-PIP01-21-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0023/2022 issued on 31 January 2022.

Having regard to the application submitted by Cytokinetics, Inc. on 20 November 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 February 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for aficamten, tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Cytokinetics, Inc., 350 Oyster Point Boulevard, 94080 - South San Francisco, CA, USA.

EMA/PDCO/543088/2023
Amsterdam, 23 February 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002958-PIP01-21-M01

Scope of the application

Active substance(s):

Aficamten

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of hypertrophic cardiomyopathy

Pharmaceutical form(s):

Tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Cytokinetics, Inc.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Cytokinetics, Inc. submitted to the European Medicines Agency on 20 November 2023 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0023/2022 issued on 31 January 2022.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 3 January 2024.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of hypertrophic cardiomyopathy

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of hypertrophic cardiomyopathy

2.1.1. Indication(s) targeted by the PIP

Treatment of symptomatic sarcomeric obstructive hypertrophic cardiomyopathy (oHCM)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet, oral use

2.1.4. Measures

Area	**Description**
Quality-related studies	**Study 1 (PED-FORMDEV-1)** Development of age-appropriate dosage strength(s)
Non-clinical studies	**Study 2 (JUV-TOX-1)** Dose range-finding juvenile toxicity study **Study 3 (JUV-TOX-2)** Definitive juvenile toxicity study
Clinical studies	**Study 4** Randomised, double-blind, placebo-controlled, 2-arm, parallel group, 2-period study to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of aficamten compared to

	placebo (Period 1) followed by long-term, open-label assessment of safety and PD (Period 2) in children from 6 years to less than 18 years of age with symptomatic sarcomeric obstructive hypertrophic cardiomyopathy (oHCM).
Extrapolation, modelling and simulation studies	**Study 5** Modelling and simulation study to support dose finding of the product in children from 6 years to less than 18 years of age with oHCM, based on data from adults and adolescents. **Study 6** Modelling and simulation study to adjust the dose of the product in children from 6 years to less than 18 years of age with oHCM, on incorporation of PK/PD data from Study 4.
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By April 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.